335 related articles for article (PubMed ID: 37804835)
1. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.
Hofman CR; Corey DR
Cell Chem Biol; 2024 Jan; 31(1):125-138. PubMed ID: 37804835
[TBL] [Abstract][Full Text] [Related]
2. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
Quemener AM; Centomo ML; Sax SL; Panella R
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
4. Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat.
Li L; Shen X; Liu Z; Norrbom M; Prakash TP; O'Reilly D; Sharma VK; Damha MJ; Watts JK; Rigo F; Corey DR
Nucleic Acid Ther; 2018 Feb; 28(1):23-33. PubMed ID: 29341839
[TBL] [Abstract][Full Text] [Related]
5. Antisense technology: an overview and prospectus.
Crooke ST; Baker BF; Crooke RM; Liang XH
Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen in the Treatment of Spinal Muscular Atrophy.
Goodkey K; Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
8. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Opportunities for Nucleic Acid Therapeutics.
Corey DR; Damha MJ; Manoharan M
Nucleic Acid Ther; 2022 Feb; 32(1):8-13. PubMed ID: 34931905
[TBL] [Abstract][Full Text] [Related]
10. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
Shen X; Corey DR
Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
12. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
Zhou T; Kim Y; MacLeod AR
Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs.
Gagnon KT; Corey DR
Nucleic Acid Ther; 2019 Jun; 29(3):116-122. PubMed ID: 30907681
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide therapeutics in neurodegenerative diseases.
Scoles DR; Pulst SM
RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
[TBL] [Abstract][Full Text] [Related]
15. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
16. [Mechanisms of action and patentability of therapeutic oligonucleotides].
Crouvezier N; Marie AC; Moumné L
Med Sci (Paris); 2023 Feb; 39(2):111-118. PubMed ID: 36799745
[TBL] [Abstract][Full Text] [Related]
17. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
18. Progress in spinal muscular atrophy research.
Wurster C; Petri S
Curr Opin Neurol; 2022 Oct; 35(5):693-698. PubMed ID: 35942665
[TBL] [Abstract][Full Text] [Related]
19. Progress on RNA-based therapeutics for genetic diseases.
Luo T; Huo C; Zhou T; Xie S
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 52(4):406-416. PubMed ID: 37643975
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide: A promising therapeutic option to beat COVID-19.
Quemener AM; Galibert MD
Wiley Interdiscip Rev RNA; 2022 Jul; 13(4):e1703. PubMed ID: 34842345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
